Retatrutide Dosage in the Research Literature — Clinic Retatrutide
What the trial doses were — at a glance
Retatrutide has been studied at doses from 0.5 mg to 12 mg subcutaneous once weekly across its Phase 1b and Phase 2 trials. Those are research design facts from published papers — not a recommended amount for any individual, and not an approved dosing standard of any kind.
Retatrutide is not an approved drug. There is no FDA label, no authorized dose range outside a clinical trial. The approximately 6-day plasma half-life is why trials used once-weekly injections.
This page summarizes what doses were studied in which trials and what outcomes were measured at those doses. The reconstitution section reflects what published research-setting protocols describe — not instructions for preparing any compound outside authorized clinical use.
Retatrutide dosage in Phase 2 and Phase 3 clinical trials was administered subcutaneous, once weekly, via a structured dose-escalation titration protocol. This page summarizes the doses studied, the titration schedules used in Lilly trials, pharmacokinetics, and reconstitution and storage conditions documented in the research literature. All dosing information is derived from published trial protocols and research reports. Retatrutide is not approved for human therapeutic use; no dose is authorized outside clinical trial enrollment.
Doses Studied in Phase 2 and Phase 3
Phase 2 obesity trial (NCT04881760): 1 mg, 4 mg, 8 mg, or 12 mg subcutaneous once weekly. Escalation from starting dose of 2 mg in increments every 4 weeks up to the target maintenance dose [1].
Phase 2 type 2 diabetes trial (NCT04867785): 0.5 mg, 4 mg, 8 mg, or 12 mg subcutaneous once weekly. Dulaglutide 1.5 mg served as active control [2].
Phase 3 TRIUMPH-1 (NCT05651776): 4 mg, 9 mg, or 12 mg subcutaneous once weekly. 80-week primary endpoint [5].
Phase 3 TRIUMPH-4: 9 mg or 12 mg subcutaneous once weekly. 68-week primary endpoint, adults with obesity and knee osteoarthritis [8].
Maximum studied dose across all trials: 12 mg once weekly subcutaneous. No once-daily formulation has been studied; the 6-day plasma half-life supports weekly-only dosing [19].
Retatrutide Dose Escalation Schedule in Phase 3
Phase 3 TRIUMPH trials initiated participants at 2.5 mg subcutaneous once weekly for weeks 1–4, then escalated in 2.5 mg increments every 4 weeks toward a target maintenance dose of 12 mg per week [5]. Phase 2 trials used similar staged escalation protocols, with starting doses of 2 mg escalating to 4, 8, and 12 mg maintenance.
Slower titration is the primary strategy for minimizing gastrointestinal adverse events. The majority of GI side effects (nausea, vomiting, diarrhea, constipation) are most frequent during initial dose escalation (weeks 1–8) and attenuate with continued use [10].
Weekly dosing ranges in research: Phase 2 minimum studied: 0.5 mg. Phase 2 maximum studied: 12 mg. Phase 3 maintenance target: 12 mg. Phase 3 lower arm: 4 mg (TRIUMPH-1).
Weekly Dosing Ranges in Retatrutide Research
Phase 2 studied five dose levels: 0.5 mg (T2D trial only), 1 mg, 4 mg, 8 mg, and 12 mg subcutaneous once weekly [1][2]. Phase 3 arms are 4 mg (lower), 9 mg (mid), and 12 mg (high). No dose above 12 mg per week has been reported in published trials.
Dose is subcutaneous injection, administered once per week. Injection site considerations follow standard subcutaneous peptide injection guidance (abdomen, thigh, upper arm).
Retatrutide Half-Life and Pharmacokinetics
Retatrutide has an approximate plasma half-life of 6 days in humans [19]. This was established in Phase 1 pharmacokinetic modeling and confirmed across Phase 2 dose groups. Pharmacokinetics are dose-proportional across the studied range of 1–12 mg.
Two structural features enable the extended half-life. First, the C20 fatty diacid moiety acylated to the peptide backbone provides albumin binding in the bloodstream, dramatically extending circulatory residence. Second, the Aib2 N-terminal substitution confers resistance to DPP-4 cleavage — DPP-4 normally degrades endogenous GLP-1 within approximately 2 minutes of secretion. Together these modifications extend the functional half-life to approximately 6 days, supporting once-weekly subcutaneous administration.
Retatrutide half-life of approximately 6 days means that plasma concentrations take approximately 4–5 weeks (about 4–5 half-lives) to reach steady-state after initiation or a dose change. This is clinically relevant for interpreting the timing of efficacy and adverse event onset in trial data.
What Happens When Retatrutide Is Discontinued?
Retatrutide-specific discontinuation follow-up data remain limited as Phase 3 TRIUMPH trials are ongoing. Based on GLP-1 receptor agonist class biology, weight regain after cessation is expected.
A systematic review and meta-regression of GLP-1 receptor agonist discontinuation studies found that pooled weight regain plateaued at approximately 75.6% (95% CI: 68.5–82.7%) of weight lost on treatment [18]. Mean regain varied by agent and follow-up duration. Slower tapering strategies and sustained lifestyle intervention have been proposed as mitigation strategies in the published literature [18].
Retatrutide-specific offboarding data are anticipated from TRIUMPH follow-up extensions. Based on the compound's 6-day half-life, plasma levels would reach undetectable ranges approximately 4–5 weeks after the last dose.
Reconstitution Procedures in Research Settings
Research protocols using lyophilized retatrutide peptide (as supplied to some research-setting uses) typically involve reconstitution with bacteriostatic water. Standard reconstitution procedure: inject bacteriostatic water slowly against the vial wall at an angle, swirl gently — do not shake, as mechanical agitation can denature peptide structure. Common concentration: 1 mL bacteriostatic water per mg of peptide yields a 1 mg/mL solution; higher concentrations reduce injection volume.
Note: Lilly's clinical trial formulations are supplied as pre-formulated solutions in autoinjector pens and are not reconstituted by participants. Research-grade lyophilized retatrutide peptides sold by peptide suppliers are not reviewed or approved by FDA for safety, efficacy, or sterility.
Mixing Retatrutide with Bacteriostatic Water
For lyophilized retatrutide in research settings, inject bacteriostatic water slowly against the inside wall of the vial — not directly onto the powder — to minimize foaming. Swirl the vial gently in slow circular motions until dissolved. Do not vortex or shake vigorously. Once reconstituted, inspect visually for clarity; discard if cloudy or particulate matter is observed.
Concentration is calculated by dividing total mg of peptide per vial by mL of bacteriostatic water added. Higher concentrations (fewer mL added) reduce injection volume but increase solution viscosity. Standard research-grade formulations are commonly prepared at 1–2 mg/mL.
Storage Conditions for Retatrutide in Research
Lyophilized retatrutide powder: stable at -20°C for long-term storage. Avoid repeated freeze-thaw cycles of lyophilized powder.
Reconstituted retatrutide solution: store at 2–8°C (standard refrigerator) and use within 28–30 days of reconstitution. Do not freeze reconstituted solution. Protect from light. These are general peptide-handling guidelines derived from published research-setting protocols.